Please assess the completion status of the following clinical trial:

Trial Title: Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Acute ischemic stroke that can be randomized within 48 hours of symptoms onset~* neurological deficit: 4 ≤ NIHSS ≤ 10~* CT or MRI scan ruling out hemorrhage or other pathology~* the first onset of ischemic stroke or previous stroke with no obvious sequelae (mRS≤1)~* Signed informed consent by patient self or legally authorized representatives~Exclusion Criteria:~* intracranial hemorrhage and hemorrhagic cerebral infarction~* Thrombolysis for ischemic stroke~* Allergy to clopidogrel and/or aspirin~* History of stroke with serious sequelae~* Severe systemic disease (such as severe infection, severe hepatic and renal dysfunction)~* Clear indication for anticoagulation (atrial fibrillation, mechanical cardiac valves, deep venous thrombosis, pulmonary embolism)~* History of intracranial hemorrhage~* Planned treatment with nonsteroidal anti-inflammatory drugs to affect platelet function~* Anticoagulation within 10 days~* Gastrointestinal bleed or major surgery within 3 months~* Planned or likely revascularization (any angioplasty or vascular surgery) within the next 3 months~* Planned surgery or intervention to stop antiplatelet therapy~* Ischemic stroke induced by angiography or surgery~* Pregnancy or childbirth within the previous 4 weeks~* Patients who have been treated with any other investigational drug within 3 months of enrollment~* Severe noncardiovascular comorbidity with life expectancy \<3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- clopidogrel plus aspirin group (Type: EXPERIMENTAL): the group will receive a 300mg loading dose of clopidogrel plus aspirin 100 mg, followed by clopidogrel 75 mg/d and aspirin 100 mg/d from day 2 to day 14, and followed by clopidogrel 75 mg/d or aspirin 100 mg/d from day 15 to day 90.
- aspirin group (Type: EXPERIMENTAL): the group will receive 100-300 mg aspirin from day 1 to day 14, followed by aspirin 100 mg/d from day 15 to day 90.

Based on this trial design, predict the completion outcome and termination type (if applicable).